Dapagliflozin for people on chronic peritoneal dialysis
Official title: Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients: A Six-month Prospective .Study
Run by Oman Ministry of Health · NCT07491042 · Data updated 2026-11-12
This will give dapagliflozin 10 mg once daily for six months to people with end-stage kidney disease on chronic peritoneal dialysis to see if it increases fluid removal and urine output.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 13 Years and up |
| Sex | All |
| Enrollment | 38 (estimated) |
| Sponsor | Oman Ministry of Health Government |
| Locations | 1 site (Nizwa) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | September 30, 2026 |
| Study ends | January 31, 2027 |
| Registry record updated | March 24, 2026 |
| Trial ID | NCT07491042 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People aged 13 or older on chronic peritoneal dialysis with urine output ≥150 ml/24h, including diabetic and non-diabetic patients who do not have type 1 diabetes or recent peritonitis, are ideal candidates.
✕Probably not a fit
Patients with urine output under 150 ml/24h, type 1 diabetes, recent PD-catheter peritonitis, recurrent UTI, peripheral vascular disease, significant liver disease, or those on hemodialysis are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
A prospective, open-label, single-arm trial at Nizwa Hospital will enroll 30 patients aged 13 and older with end-stage kidney disease on chronic peritoneal dialysis, including both diabetic and non-diabetic participants. All participants will receive dapagliflozin 10 mg once daily and undergo clinical and laboratory assessments at baseline, three months, and six months. Primary outcomes are change in peritoneal ultrafiltration volume, dialysis adequacy (Kt/V), and mean 24-hour urine volume. The study runs from March 1 to August 31, 2026, and excludes patients with type 1 diabetes, low urine output (<150 ml/24h), recent peritonitis, recurrent UTI, peripheral vascular disease, or significant liver disease.
Why it matters
Potential benefit: If successful, dapagliflozin could increase peritoneal ultrafiltration and urine output, improving volume control and dialysis adequacy for people on PD.
How similar studies have gone: SGLT2 inhibitors have shown kidney and cardiovascular benefits in earlier CKD trials and animal studies indicate possible peritoneal effects, but use in peritoneal dialysis patients is novel with only limited mechanistic or small-scale data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * o age equal to or more than13 years. * All genders. * All patients undergoing chronic Peritoneal Dialysis. * Urine output equal or more than 150 ml/24 hours. Exclusion Criteria: * o Age less than 13 years * Patients with type I diabetes mellitus. * Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D). * Patients with urine output less than 150 ml/24hours. * Patients with recurrent hypoglycemic episodes * Patients with acute or chronic liver disease, * Patients who refuse to participate in the study. * peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months
Where it's running
-
Jehad Badawi AL LAHAM
Nizwa, Oman Recruiting
Study contacts
- Study coordinator: Jehad Badawi B AL LAHAM
- Email: sarkosyr@gmail.com
- Phone: 94478719
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized High-Rate Fluid Removal Guided by Ultrasound in Hospitalized ESRD with Fluid Overload
This trial tests whether using ultrasound to guide a higher rate of fluid removal is as safe and effective as standard fluid removal for adults with end-stage kidney disease who are admitted for severe fluid overload.
-
Choosing dialysis: what matters most to patients
This project uses a questionnaire to see which factors, including possible financial compensation, influence dialysis choices among adults with advanced kidney failure who are considering dialysis options.
-
Storing deceased donor kidneys at 10°C instead of on ice (4°C)
This trial will try to see if deceased donor kidneys stored at 10°C help adult transplant recipients have better kidney function after transplant compared with kidneys stored on ice (4°C).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.